KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of G12C-inhibitors compared to chemotherapy in second line and beyond in adults with advanced/metastatic non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma (KRAS) G12C mutation.
Authors
- Kim de Jong (ORCID: https://orcid.org/0000-0002-7621-9290)
- Wouter Heero van Geffen
- Anneloes L. Noordhof (ORCID: https://orcid.org/0000-0002-6269-6766)
- Oke Dimas Asmara (ORCID: https://orcid.org/0000-0001-9859-2267)
- F Van Vollenhoven
- Ben J.W. Venmans
- Lizza Hendriks
- Ymkje MA Huitema
- Rolof GP Gijtenbeek
Institutions
- Radboud University Nijmegen (NL)
- Fryske Akademy (NL)
- Maastricht University Medical Centre (NL)
- Medisch Centrum Leeuwarden (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Maastro Clinic (NL)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1002/14651858.cd016054
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00